Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages

Omeros Corporation (NASDAQ:OMER) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $33.6667.

A number of analysts recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Wednesday, December 24th. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Wednesday, December 24th. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th.

Omeros Price Performance

Shares of OMER stock opened at $17.17 on Friday. The firm has a 50-day moving average of $9.79 and a 200-day moving average of $6.18. Omeros has a one year low of $2.95 and a one year high of $17.65. The company has a market cap of $1.22 billion, a P/E ratio of -8.50 and a beta of 2.37.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. As a group, research analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several large investors have recently modified their holdings of OMER. Russell Investments Group Ltd. raised its holdings in shares of Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the period. Trexquant Investment LP purchased a new stake in Omeros in the first quarter worth $88,000. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros in the second quarter worth $32,000. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Finally, Sei Investments Co. purchased a new position in shares of Omeros during the 2nd quarter valued at $40,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.